The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most squamous cell carcinomas and many cases of urothelial cancers exhibited moderate to strong cytoplasmic immunoreactivity. A few cases of malignant melanomas, endometrial cancers and testicular embryonal cancers showed moderate staining. Malignant cells in general were negative.
Most squamous cells carcinomas and urothelial cancers showed strong cytoplasmic and nuclear immunoreactivity. Moderate to strong positivity was observed in several malignant melanomas, testicular, colorectal and gastric cancers as well as small fractions of cases the most of the remaining cancers. Malignant gliomas, malignant lymphomas, breast, prostate, ovarian, renal and liver cancers were generally negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
